anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
One cycle of therapy is 4 weeks (28 days), the subjects in the experimental group will receive albumin-bound paclitaxel 100 mg/m2 iv drip on Day 1 (D1), D8 and D15 of each cycle, and EOC202 30 mg subcutaneously on D2 and D16 of each cycle; the subjects in the control group will receive albumin-bound paclitaxel 100 mg/m2 iv drip on D1, D8 and D15 of each cycle. The treatment will continue until progression of disease, death, intolerable toxicity, start of other antitumor therapy, withdrawal of informed consent, loss of follow-up or termination of study for other reasons, whichever comes first.
The group denominated SP received a teaching strategy based on a class session with simulated practice for decision-making in clinical skills when caring for a person with LBP. Each session lasted approximately 120 minutes, and the clinical case used for the SP sessions was subjected to face validity with experts in the area of study.
The U.S. Food and Drug Administration approved vortioxetine to treat major depressive disorder in 2013. Researchers believe vortioxetine may improve pattern separation and pattern completion (i.e., a neurological function) in people with major depressive disorder; thus, this research study aims to determine how vortioxetine increases a person's ability to think. The current study is an open label trial, therefore, all participants will receive vortioxetine. Furthermore, participants receive the vortioxetine at no cost. It will take participants 6 weeks to complete this study. Participants are asked to come to the Mass General Hospital campus for 1 screening visit which includes a full psychiatric evaluation, and 5 additional study visits. During study visits, participants will meet with a clinician and then complete computer based cognitive tests.
FIELD: medicine. SUBSTANCE: method involves protecting water against contact with ambient air, mechanical and temperature actions on the way of its passage from well to procedure room by filling reservoir with water jet under its mirror formed to completely force air out from the reservoir and overflow the reservoir volume to 5-10 % of the whole volume and sealing the reservoir. Water is stored by pouring it into the accumulating reservoir with overflow. Water discharge is carried out from beneath from space under the water mirror in transporting reservoir. Water is supplied from under its mirror in the accumulating reservoir and instantaneously heated to 37-38 C by dividing water flow into thin threads. EFFECT: minimized losses of curative properties. 3 cl, 2 dwg
Rheumatoid arthritis (RA) is the most common inflammatory joint disease, and early diagnosis is key for effective disease management. CD69 is one of the earliest cell surface markers seen at the surface of activated immune cells, and CD69 is upregulated in synovial tissue in patients with active RA. In this study, we evaluated the performance of a CD69-targeting PET agent, [68Ga]Ga-DOTA-ZCAM241, for early disease detection in a model of inflammatory arthritis. Methods: A model of inflammatory arthritis was induced by transferring splenocytes from KRN T-cell receptor transgenic B6 mice into T-cell-deficient I-Ag7 major histocompatibility complex class II-expressing recipient mice. The mice were examined longitudinally by [68Ga]Ga-DOTA-ZCAM241 PET/CT before and 3, 7, and 12 d after induction of arthritis. Disease progression was monitored by clinical parameters, including measuring body weight and scoring the swelling of the paws. The uptake of [68Ga]Ga-DOTA-ZCAM241 in the paws was analyzed and expressed as SUVmean Tissue biopsy samples were analyzed for CD69 expression by flow cytometry or immunostaining for a histologic correlate. A second group of mice was examined by a nonbinding, size-matched Affibody molecule as the control. Results: Clinical symptoms appeared 5-7 d after induction of arthritis. The uptake of [68Ga]Ga-DOTA-ZCAM241 in the joints was negligible at baseline but increased gradually after disease induction. An elevated PET signal was found on day 3, before the appearance of clinical symptoms. The uptake of [68Ga]Ga-DOTA-ZCAM241 correlated with the clinical score and disease severity. The presence of CD69-positive cells in the joints and lymph nodes was confirmed by flow cytometry and immunostaining. The uptake of the nonbinding tracer that was the negative control also increased gradually with disease progression, although to a lesser extent than with [68Ga]Ga-DOTA-ZCAM241 Conclusion: The uptake of [68Ga]Ga-DOTA-ZCAM241 in the inflamed joints preceded the clinical symptoms in the KRN T-cell transfer model of inflammatory arthritis, in accordance with immunostaining for CD69. [68Ga]Ga-DOTA-ZCAM241 is thus a promising PET imaging marker of activated immune cells in tissue during RA onset.
A total of 859 adults with CABP were randomized in a multicenter, multinational, double-blind, double-dummy, noninferiority trial comparing BAXDELA to moxifloxacin (Trial 3, NCT 02679573). In this trial, BAXDELA for injection 300 mg was administered intravenously (IV) every 12 hours with an option to switch to BAXDELA tablet 450 mg orally every 12 hours. Moxifloxacin 400 mg was administered IV every 24 hours with an option to switch to moxifloxacin tablet 400 mg orally every 24 hours. Switch to oral treatment was allowed after a minimum of 3 days of IV dosing. Total treatment duration was 5 to 10 days. In the moxifloxacin arm, the investigator could switch patients to linezolid 600 mg every 12 hours if methicillin-resistant Staphylococcus aureus (MRSA) was confirmed.

A total of 431 patients were randomized to BAXDELA and 428 to moxifloxacin. Patient demographic and baseline characteristics were balanced between the treatment arms. In this trial, 12.9% of patients were in PORT Risk Class II, 60.3% were in PORT Risk Class III, 25.4% were in PORT Risk Class IV, and 1.4% were in PORT Risk Class V. The average age of patients was 60 years (range 18 to 93 years). Patients were predominantly male (58.7%) and white (91.5%); average BMI was 26.9 kg/m2. Associated comorbidities included pre-existing pulmonary disease (13.6%), cardiac disease (23.9%), diabetes (15.3%), and mild to severe renal impairment (76.9%). Bacteremia was documented at baseline in 1.5% of patients. The majority of sites were in Eastern Europe, which accounted for 82.8% of enrollment. One subject (0.2%) was enrolled in the BAXDELA arm and 5 (1.2%) in the moxifloxacin arm from the United States.

Early clinical response (ECR) at 72-120 hours after the first dose was defined as survival with improvement in at least two of four symptoms (cough, sputum production, chest pain, dyspnea) from baseline without deterioration in any of these symptoms, and without use of additional antimicrobial therapy for treatment of the current CABP infection due to lack of efficacy.

Clinical response was also assessed by the investigator at the test of cure (TOC) visit and defined as survival with resolution or near resolution of the symptoms of CABP present at study entry, and no use of additional antimicrobial therapy for the current CABP infection, and no new symptoms associated with the current CABP infection.

Clinical response rates at the TOC visit for the ITT and Clinically Evaluable (CE) populations are presented in Table 11.

Early clinical response and investigator-assessed clinical response at the TOC visit is presented in Table 12 by baseline pathogen for the Microbiological ITT (MITT) population which comprised all randomized patients who had a baseline pathogen identified that is known to cause CABP.
PROBLEM TO BE SOLVED: To obtain a new compound acting selectively on cancer cells, low in toxicity to normal cells, and useful as a highly safe antitumor agent. SOLUTION: This new compound is shown by the formula (R<1> and R<2> are each H or OH, when R<1> is OH, R<2> is H, and when R<1> is H, R<2> is OH), e.g. 2-acetyl-5-hydroxynaphtho(2,3-b)furan-4,9-dione. The compound of the formula is obtained (isolated), for example, by the following process: the bark of Tecoma ipe Mart. ex K.Shum.=Tabebuia avellanedae Lor. ex Griseb. as a tree belonging to the genus Campsis chinensis is subjected to extraction with methanol, from the residues obtained by distilling off the methanol, chloroform solubles is collected and then put to chromatography. The compound of the formula can be used as a medicine for treating various malignant tumors such as solid carcinoma in various organs, hematological malignancy and sarcoma, its daily dose being pref. 20-1,000 mg/adult.
Oxygen, intravenous fluids, vasopressors, and other supportive measures should be employed as indicated. Assisted or controlled ventilation should also be considered. For respiratory depression due to overdosage or unusual sensitivity to pentazocine hydrochloride and acetaminophen tablets, parenteral naloxone is a specific and effective antagonist.

The toxic effects of acetaminophen may be prevented or minimized by antidotal therapy with N-acetylcysteine. In order to obtain the best possible results, N-acetylcysteine should be administered within approximately 16 hours of ingestion of the overdose.

For complete prescribing information for the approved use of acetylcysteine in the treatment of acetaminophen overdose, see the package insert for acetylcysteine.

Vigorous supportive therapy is required in severe intoxication. Procedures to limit the continuing absorption of the drug must be readily performed since the hepatic injury is dose dependent and occurs early in the course of intoxication. Induction of vomiting or gastric lavage, followed by oral administration of activated charcoal should be done in all cases.

If hemodialysis can be initiated within the first 12 hours, it is advocated for patients with a plasma acetaminophen concentration exceeding 120 mcg/mL at 4 hours after ingestion of the drug.
The present invention relates to dried powder of aizoon stonecrop herb. The present invention relates to dried powder of a plant. The purpose of the present invention is to solve the problem that aizoon stonecrop herb which is a plant used as not only medicine but also as food is mainly used for making dishes, and the medical value of the aizoon stonecrop herb is not completely developed. Aizoon stonecrop herb is dried, crushed and ground to form the present invention. After the present invention is made, the particle size of the dried powder is 500 meshes to 10000 meshes (super fine powder). After the present invention is continuously eaten for three months, the everyday dose is not limited, and eaters feel well in general three months later. In the past, disease symptoms, such as cardiopalmus, palpitation, precordial discomfort, headache, dizziness, numb limbs and tense tendons, etc., which are caused by insufficient blood supply of coronary artery of a heart, slight embolism of cerebral arteries to moderate embolism of cerebral arteries, and insufficient or deficient blood supply of a brain, essentially disappear. After the eaters are examined in hospitals, the blood supply of coronary arteries, cardiac muscles and brains of the eaters is obviously improved. Especially, the blood fat of the eaters descends in different grades. The present invention has the advantages that the present invention can be conveniently eaten, angiocardiopathy andcerebrovascular diseases can be effectively relieved, the blood fat is reduced, and the present invention has no toxic side effect.
Tubal flushing during HSG HSG will be performed by a gynaecologist, fertility doctor or nurse according to local protocols. HSG will be performed in the follicular phase of the cycle. Preferably, HSG is performed in the next cycle after randomization, but if this is not feasible the procedure may be postponed up till one month after randomization. After cleaning the vagina and cervix, a vacuum cervix adapter will be applied to the cervix or a Lipiodol resistant balloon catheter or hysterophore will be placed through the cervix. Up to 15ml of Lipiodol Ultra Fluid will be injected into the uterine cavity and its spread directly monitored by fluoroscopy. Six to eight radiographs will be taken and assessed by a gynaecologist or radiologist. The maximum amount of oil-based contrast medium is set at 15ml.
PURPOSE: To examine the association of prepregnancy dietary patterns with postpartum weight retention at 6 months (PPWR6) among Lebanese and Qatari women.
METHODS: Data for this study were derived from the Mother and Infant Nutrition Assessment (MINA) prospective cohort study conducted in Lebanon and Qatar. Pregnant women were recruited during their first trimester and were followed up for three years. For the purpose of this study, data belonging to sociodemographic characteristics of participants, prepregnancy dietary intake, prepregnancy BMI as well as weight retention at 6 months were used. Dietary intake was examined using a 98-item food frequency questionnaire. Principal component analysis was used for the derivation of dietary patterns. The associations of dietary patterns with PPWR6 were examined using simple and multiple linear regressions.
RESULTS: Data was available for 177 participants (Lebanon: 93; Qatar: 84). Mean PPWR6 was 4.05 ± 5.29 kg. Significantly higher PPWR6 was observed among participants with pre-pregnancy overweight/obesity and among those with excessive gestational weight gain. Two dietary patterns were identified: the "Western" and the "Varied" patterns. After adjustment for confounders, a positive association was observed between the 'Western' pattern scores and PPWR6 (ß = 1.27; 95% CI 0.68-1.86; p value: < 0.0001).
CONCLUSION: Higher adherence to the Western pattern was associated with higher PPWR6 amongst women, hence underscoring the importance of public health interventions aimed at fostering healthier dietary habits during this crucial stage of the lifecycle.
Albumin and doxorubicin are processed through a bonding reaction to be purified with water in a column. The bonded albumin and doxorubicin are added with a nano-gold solution for reaction. After being purified, the solution phase is changed to a phosphate buffer for obtaining a nano-gold-doxorubicin anticancer drug. Thus, with the high biocompatibility and the high surface area, the nano-gold solution is used in biological applications as a carrier for increasing accumulation of drug on tumor. The bonding between nano-gold and doxorubicin increases stability of doxorubicin. Besides, doxorubicin has tumor-killing effect, so effective therapy for cancer can be achieved.
The present invention relates to a Chinese medicinal preparation for curing climacteric syndrome in the type of liver depression and qi stagnation, and a preparation method thereof. The present invention belongs to the technical field of Chinese medicine, and is used for achieving the technique of a Chinese medicinal preparation for curing climacteric syndrome in the type of liver depression and qi stagnation and a preparation method thereof. The medicinal preparation uses bupleurum root, angelica, white peony alba, tuckahoe, largehead atractylodes rhizome, radix glycyrrhiza, mint, flos inulae, ruddle, cortex magnoliae officinalis, rhizoma cyperi, radix rehmanniae, radices curcumae, fructus tritici levis, stir-baked semen ziziphi spinosae, lily, fossilia ossis mastodi, caulis polygoni multiflori and common aucklandia root as raw materials, and can be in the preparation forms of pulvis, pills, capsules or decoction which can be prepared through proportioning, decoction and sterilized package. The medicinal preparation can perform the favorable curative effect on menopausic ademosyne, vexation, agitation, irascibility, insomnia, palpitation, severe palpitation, amnesia, tumefaction and pain of the costa, pharyngoxerosis, aryngemphraxis, irregular menstruation, rubeosis, night sweat, etc., and has rapid effect and outstanding curative effects. In clinical observation, the effective rate reaches more than 90%. The medicinal preparation is a compound pure Chinese medicinal preparation, can be preserved for a long time, has eligible mouth feel, and is convenient to take.
<P>PROBLEM TO BE SOLVED: To provide a new composition for dyeing keratinous fibers that make it possible to obtain strong, chromatic, aesthetic and sparingly selective coloring in coppery shades, which shows good resistance to various attacking factors to which hair may be subjected, such as shampoo, light, sweat and permanent reshaping operations.  <P>SOLUTION: The composition for dyeing the keratinous fibers comprises 2,3-diamino-6,7-dihydro-1H,5H-pyrazolo[1,2-a]pyrazol-1-one as a first oxidation base, 6-chloro-2-methyl-5-aminophenol as a first coupler and a substituted m-aminophenol of prescribed formula as a second coupler. It is understood that the molar ratio of the first oxidation base/first coupler is <1.5, the molar ratio of the first oxidation base/second coupler is >1 and the molar amount of the first oxidation base is ≥2.5×10<SP>-3</SP>mol based on 100 g of the composition. The strong, very chromatic, aesthetic, sparingly selective and fast coloring of the keratinous fibers in the coppery shades can be obtained. Furthermore, the strong coloring can be obtained at a neutral pH.  <P>COPYRIGHT: (C)2008,JPO&INPIT
The purpose of this study is to determine how multifocal contact lenses affect contact lens comfort in non-presbyopic contact lens wearers. Current soft contact lens wearers who have symptoms of discomfort in their contact lenses will be recruited. Each subject (n = 84) will wear a single vision soft contact lens (Ultra single vision spherical lens) for two weeks and a low add power multifocal (Ultra for Presbyopia) for two weeks. Half of the subjects will wear the single vision lens first, and half of the subjects will wear the multifocal lens first. Initial lens group will be chosen randomly. Subjects will complete surveys that assess their vision and comfort which each lens, and ocular surface and accommodative/binocular vision status will be evaluated at the initial dispense and after wearing each lens for two weeks.
Nitrogen dioxide (NO2) represents a deleterious effect on acute myocardial infarction (AMI), but few relevant studies have been conducted in China. We aim to evaluate the acute effects of NO2 exposure on hospitalization for AMI in Lanzhou, China. In this study, we applied a distributional lag nonlinear model (DLNM) to assess the association between NO2 exposure and AMI hospitalization. We explored the sensitivity of various groups through stratified analysis by gender, age, and season. The daily average concentration of NO2 is 47.50 ± 17.38 µg/m3. We observed a significant exposure-response relationship between NO2 concentration and AMI hospitalization. The single pollutant model analysis shows that NO2 is positively correlated with AMI hospitalization at lag1, lag01, lag02, and lag03. The greatest lag effect estimate occurs at lag01, where a 10 µg/m3 increase in NO2 concentrations is significantly associated with a relative risk (RR) of hospitalization due to AMI of 1.027 [95% confidence interval (CI): 1.013, 1.042]. The results of the stratified analysis by gender, age, and season indicate that males, those aged ≥65 years, and the cold season are more sensitive to the deleterious effects caused by NO2 exposure. Short-term exposure to NO2 can enhance the risk of AMI hospitalization in urban Lanzhou.Implications: Exposure to particulate matter can lead to an increased incidence of AMI. Our study once again shows that NO2 exposure increases the risk of AMI hospital admission. AMI is a common and expensive fatal condition. Reducing NO2 exposure will benefit cardiovascular health and save on healthcare costs.
A method is provided for determining whether a third party is authorized to access information representative of genetic data. This information representative of genetic data is associated with a physical sample and is provided in an accessible format. A set of access rights is received that define which third parties can access the information and how the information can be used. A third party requests to access the information for the purposes of performing a test. The request is compared to the access rights. If the third party is authorized, the test is performed on the information. If, however, the third party is not authorized, access is denied.
OBJECTIVE: Hepatitis B virus (HBV) infection causes substantial harm to mitochondrial activity, which hinders the development of effective treatments for chronic hepatitis B (CHB). The discovery of the mitochondrial-derived short peptide MOTS-c, which possesses multiple bioactivities, offers a promising new approach in treating HBV infection. This study aims to explore the diagnostic and therapeutic potential of MOTS-c in HBV-related diseases and its molecular mechanism.
DESIGN: In total, 85 healthy subjects and 404 patients with HBV infection, including 20 clinical treatment cohorts, were recruited for this study. MOTS-c levels were measured by ELISA and its diagnostic value was evaluated by receiving operating characteristic curve analysis. The therapeutic effect of MOTS-c was observed in multiple HBV-infected mice and cells through various techniques, including transcriptomic sequencing, flow cytometry, immunofluorescence and electron microscopy. Additionally, MOTS-c's potential interaction with myosin-9 (MYH9) and actin was predicted using immunoprecipitation, proteomics and target prediction software.
RESULTS: MOTS-c negatively correlates with HBV DNA expression (R=-0.71), and its AUC (the area under the curve) for distinguishing CHB from healthy controls is 0.9530, and IA (immune reactive) from IC (inactive HBV carrier) is 0.8689. Inhibition of HBV replication (with a 50-70% inhibition rate) was observed alongside improved liver function without notable toxicity in vitro or in vivo. MOTS-c was found to promote mitochondrial biogenesis and enhance the MAVS (mitochondrial antiviral signalling protein) signalling pathway. The impact is dependent on MOTS-c's ability to regulate MYH9-actin-mediated mitochondrial homeostasis.
CONCLUSION: MOTS-c has the potential to serve as a biomarker for the progression of HBV infection while also enhancing antiviral efficacy. These findings present a promising innovative approach for effectively treating patients with CHB. Furthermore, our research uncovers a novel role for MOTS-c in regulating MYH9-actin-mediated mitochondrial dynamics and contributing to mitochondrial biogenesis.
INTRODUCTION: The Weight-Adjusted Waist Index (WWI) is a new indicator of obesity that is associated with all-cause mortality in Asian populations. Our study aimed to investigate the linear and non-linear associations between WWI and all-cause mortality in non-Asian populations in the United States, and whether WWI was superior to traditional obesity indicators as a predictor of all-cause mortality.
METHODS: We conducted a cohort study using data from the 2011-2018 National Health and Nutrition Examination Survey (NHANES), involving 18,592 participants. We utilized Cox proportional hazard models to assess the association between WWI, BMI, WC, and the risk of all-cause mortality, and performed subgroup analyses and interaction tests. We also employed a receiver operating characteristics (ROC) curve study to evaluate the effectiveness of WWI, BMI, and WC in predicting all-cause mortality.
RESULTS: After adjusting for confounders, WWI, BMI, and WC were positively associated with all-cause mortality. The performance of WWI, BMI, and WC in predicting all-cause mortality yielded AUCs of 0.697, 0.524, and 0.562, respectively. The data also revealed a U-shaped relationship between WWI and all-cause mortality. Race and cancer modified the relationship between WWI and all-cause mortality, with the relationship being negatively correlated in African Americans and cancer patients.
CONCLUSIONS: In non-Asian populations in the United States, there is a U-shaped relationship between WWI and all-cause mortality, and WWI outperforms BMI and WC as a predictor of all-cause mortality. These findings may contribute to a better understanding and prediction of the relationship between obesity and mortality, and provide support for effective obesity management strategies.